An AI drug specialist zeroes in on rare forms of obesity

Summary

Superluminal Medicines secured $60 million in funding to develop a selective obesity drug candidate designed to work similarly to Rhythm Pharmaceuticals' marketed medicine Imcivree, targeting rare forms of obesity.